Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems (Hybrid CATT1)
Hybrid CATT1: Hybrid Closed Loop Insulin Pumps With Cadisegliatin as Adjunctive Treatment in Patients With Type 1 Diabetes A Phase 2a Double Blind Randomized Cross-Over Study
TTP399-206 is a Phase 2a multicenter double blind cross over randomized study of cadisegliatin in participants with T1D using hybrid closed loop systems to manage their diabetes. Participants using a hybrid closed loop insulin pump to manage their diabetes will be randomized to either receive blinded cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment or placebo QD along with their insulin treatment. The trial begins with a screening period of up to 2 weeks, followed by a device training and insulin adjustment period of 1-2 weeks leading into the first double-blind treatment period of 6 weeks. There will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participants will cross-over to the treatment that they did not receive in the first treatment period.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
TTP399-206 is a 20 week, Phase 2a trial designed to evaluate efficacy and safety of cadisegliatin in participants with T1D who are using hybrid closed loop (HCL) systems to manage their condition to gather preliminary data to understand how cadisegliatin performs in an HCL setting.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Meaghan Marnell
- Telefonnummer: (336) 888-0435
- E-mail: clinicaltrials@vtvtherapeutics.com
Studiesteder
-
-
California
-
Modesto, California, Forenede Stater, 95355
- Rekruttering
- Paradigm Clinical Research -Modesto
-
Ledende efterforsker:
- Gopika Gangupantula, MD
-
San Diego, California, Forenede Stater, 92108
- Rekruttering
- Paradigm Clinical Research Centers, LLC
-
Ledende efterforsker:
- Schafer Boeder, MD
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- Barbara Davis Center for Diabetes
-
Ledende efterforsker:
- Halis Kaan Akturk, MD
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30318
- Rekruttering
- Atlanta Diabetes Associates
-
Ledende efterforsker:
- Bruce W Bode, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27514
- Rekruttering
- UNC Eastowne Medical Office Building
-
Ledende efterforsker:
- Klara Klein, MD, PhD
-
-
Texas
-
Austin, Texas, Forenede Stater, 78731
- Rekruttering
- Texas Diabetes & Endocrinology, P.A.
-
Ledende efterforsker:
- Thomas Blevins, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Participants >= 18 years of age
- Fasting C-peptide levels <0.6 ng/ml
- Average TIR < 70% recorded on their personal CGM data collected over the past 7 days prior to Visit 1
- Currently on a hybrid closed loop device for at least 3 months and willing to stay on the same model of pump device for study duration
- Willing to wear a study provided CGM for study duration
- Total bilirubin ≤2×ULN, ALT and AST ≤3×ULN
Key Exclusion Criteria:
- Have Type 2 Diabetes Mellitus (DM), monogenic diabetes, maturity-onset diabetes, other unusual or rare forms of DM, or diabetes resulting from a secondary disease.
- Have been hospitalized for DKA within 3 months
- Have uncontrolled hypothyroidism or hyperthyroidism
- Have QTcF interval > 450 msec for males or > 470 msec for females
- Have a personal or family history of long QT syndrome, Torsades de pointes, or other complex ventricular arrhythmias
- Have persistent, uncontrolled hypertension
- Have clinically significant cardiovascular or cerebrovascular disease
- Have proliferative retinopathy or maculopathy requiring acute treatment
- Have a serious concomitant systemic disorder including but not limited to HIV or active Hep B or Hep C
- Have been diagnosed and/or treated for malignancy within 3 years
- Have used any of the following medications within the specified time periods: any non-insulin anti-diabetic therapies (e.g.SGLT-2 inhibitors, GLP-1 receptor agonists, metformin, sulfonylureas, DPP-4 inhibitors, pramlintide, a-glucosidase inhibitors, or glucose dependent insulinotropic polypeptide agonists) within 30 days, antipsychotic medications (e.g. olanzapine, risperidone, clozapine, quetiapine, and haloperidol) within 30 days, systemic corticosteroids for ≥7 days for a temporary medical condition within 30 days,
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Cadisegliatin 800 mg QD, then Placebo
If a participant is randomized to receive cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the placebo QD along with their insulin treatment |
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin
Andre navne:
Placebo (insulin alone) |
|
Eksperimentel: Placebo, then Cadisegliatin 800 mg QD
If a participant is randomized to receive placebo QD along with their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment |
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin
Andre navne:
Placebo (insulin alone) |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
To assess the change in Time in Range (TIR)
Tidsramme: last 2 weeks of the two 6-week treatment periods
|
Time in Range (TIR) based on study CGM in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo |
last 2 weeks of the two 6-week treatment periods
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
CGM-based metric for glycemic control
Tidsramme: last 2 weeks of each treatment period
|
Time In Tight Range (TITR) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Tidsramme: last 2 weeks of each treatment period
|
Time Above Range (TAR) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Tidsramme: last 2 weeks of each treatment period
|
Time Below Range (TBR) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Tidsramme: last 2 weeks of each treatment period
|
Glucose Management Indicator (GMI) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Tidsramme: last 2 weeks of each treatment period
|
Glucose variability (GV) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Tidsramme: last 2 weeks of each treatment period
|
Time in Range (TIR) > 70% |
last 2 weeks of each treatment period
|
|
Change in glucose control after standardized mixed meal tolerance test (MMTT)
Tidsramme: 12 weeks
|
Glucose Peak Plasma Concentration (Cmax) based on study CGM after standardized mixed meal tolerance test (MMTT) |
12 weeks
|
|
Change in glucose control after standardized mixed meal tolerance test (MMTT)
Tidsramme: 12 weeks
|
Glucose Area under the plasma concentration versus time curve (AUC) based on study CGM after standardized mixed meal tolerance test (MMTT) |
12 weeks
|
|
To assess the change in Level 1, Level 2 , and Level 3 hypoglycemic incidence
Tidsramme: 12 weeks
|
Number of events of Level 1 and Level 2 hypoglycemia as determined by CGM and Level 3 hypoglycemic events in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo |
12 weeks
|
|
Assess incidence of Serious Adverse Events (SAEs)
Tidsramme: 14 weeks
|
Number of Serious Adverse Events (SAEs) |
14 weeks
|
|
Assess incidence of Treatment Emergent Adverse Events (TEAEs)
Tidsramme: 14 weeks
|
Number of treatment emergent adverse events (TEAEs) |
14 weeks
|
|
Assess incidence of Treatment Emergent Adverse Events (TEAEs) leading to discontinuation
Tidsramme: 14 weeks
|
Number of treatment emergent adverse events (TEAEs) leading to discontinuation of study drug |
14 weeks
|
|
Assess incidence of Adverse Events of Special Interest (AESIs)
Tidsramme: 14 weeks
|
Number of adverse events of special interest (AESIs) |
14 weeks
|
|
Change from baseline in average daily total insulin dose
Tidsramme: last week of the two 6-week treatment periods
|
Change from baseline in average daily total insulin dose in units (IU) based on manual entry in eDiary records from participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo |
last week of the two 6-week treatment periods
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Maria Alba, MD, vTv Therapeutics LLC
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- TTP399-206
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .